Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at chemotherapy for advanced cancer of the pancreas (GEM-CAP)

Overview

Cancer types:

Pancreatic cancer

Status:

Results

Phase:

Phase 3

Details

This trial compared gemcitabine alone with gemcitabine and capecitabine (Xeloda) for advanced pancreatic cancer. This trial was supported by Cancer Research UK.

Unfortunately, most people with pancreatic cancer cannot have surgery to cure their cancer because it is too advanced when it is diagnosed. Doctors believe that giving chemotherapy helps patients by improving symptoms.

Doctors often use a chemotherapy drug called gemcitabine. In this trial, they wanted to see if having capecitabine chemotherapy tablets alongside gemcitabine helped.

The aim of the trial was to see if having gemcitabine and capecitabine together is better than having gemcitabine alone for advanced cancer of the pancreas.

Recruitment start: 20 May 2002

Recruitment end: 18 January 2005

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr D Cunningham

Professor J Neoptolemos

Janet Dunn

Supported by

Cancer Research UK

NIHR Clinical Research Network: Cancer

Other information

This is Cancer Research UK trial number CRUK/01/008.

Last reviewed: 23 November 2015

CRUK internal database number: 106

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.